You are not logged in
You need to be a member to print this page.
Sign up for free membership, or log in.
Find out more about our membership benefits
2009, Volume 16, Supplement 2
NEWS
Br J Cardiol 2009;16(Suppl 2):S1-S2
Maximising safety and efficacy in the treatment of wet AMD
The prevalence of neovascular age-related macular degeneration (wet AMD) is predicted to rise to more than 300,000 patients in the UK alone by the year...
NEWS
Br J Cardiol 2009;16(Suppl 2):S3-S8
Current treatment of wet age-related macular degeneration: determining the cardiovascular risk
Age-related macular degeneration (AMD) is a common ocular condition that may destroy central vision and has a devastating effect on the patient’s quality of life....
NEWS
Br J Cardiol 2009;16(Suppl 2):S9-S10
VEGF function in ocular health and disease: implications for therapeutic intervention in wet AMD
Vascular endothelial growth factor (VEGF) plays a pivotal role in stimulating abnormal neovascularisation, a key characteristic of neovascular age-related macular degeneration (so-called wet AMD).1 VEGF...
NEWS
Br J Cardiol 2009;16(Suppl 2):S11-S13
Wet AMD: anti-VEGF treatments in the elderly population
In 1971 Folkman proposed that tumour growth was dependent upon angiogenesis, and consequently suggested that preventing angiogenesis might prevent tumour growth.1 This concept led to...
NEWS
Br J Cardiol 2009;16(Suppl 2):S14-S15
Efficacy and safety of intravitreal pegaptanib sodium in the treatment of neovascular age-related macular degeneration
egaptanib sodium (Macugen®) was approved for the treatment of neovascular AMD (wet AMD) in Europe in 2006. It is administered by intravitreal injection into the...